Venture Life Regulatory News (VLG)

Venture Life Group PLC

("Venture Life" or the "Company" or the "Group")

Product registrations finalized in China

Bracknell, UK - 13 January 2016: Venture Life Group plc (AIM: VLG), the international consumer healthcare group addressing the self-care needs of the ageing population, which announced an extension to its existing exclusive partnering deal with Gialen in China on 23 December 2015, confirmed then that 13 of the 15 Classic Range products submitted for registration under the original deal had been registered.

The Group can now confirm that the remaining two products have also been registered and are currently in production.

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer +44 (0)1344 742 870

James Hunter, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Broker) Freddy Crossley +44 (0) 20 7886 2500

Peter Steel

Duncan Monteith Corporate Finance

Tom SalvesenCorporate Broking

Square1 Consulting

David Bick

Brian Alexander +44 (0)20 7929 5599

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

· food supplements to maintain brain function and memory;  · dermo-cosmetics for addressing the signs of skin ageing and hair loss, and  · medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.